William F. Doyle - 03 Mar 2026 Form 4 Insider Report for NovoCure Ltd (NVCR)

Reporting relationship: Executive Chairman, Director
Issuer ticker: NVCR
Reported as of: 03 Mar 2026
Net transaction value: -$932,883
SEC form: 4
Accepted by SEC: 05 Mar 2026, 16:30:44 UTC
Prior SEC filing: 02 Jun 2025
Next SEC filing: 29 May 2026
Source filing: View source filing
Reporting owner signature: Steven Robbins, as attorney in fact for Doyle, William F

Key filing fact

William F. Doyle filed Form 4 for NovoCure Ltd (NVCR) on 05 Mar 2026.

Key facts

This page summarizes William F. Doyle's Form 4 filing for NovoCure Ltd (NVCR).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Mar 2026, 16:30.

Change

Previous filing in this sequence was filed on 02 Jun 2025.
Current net transaction value: -$932,883.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001194459 Primary reporting owner

DOYLE WILLIAM F

Relationship: Executive Chairman, Director
Address: C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE
Signature: Steven Robbins, as attorney in fact for Doyle, William F
Signature date: 05 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCR transaction

Ordinary Shares

Award

Transaction value
Shares: +200,000
Change %
Price: $0.000000^*
Shares after: 200,000
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F1

NVCR transaction

Ordinary Shares

Award

Transaction value
Shares: +200,284
Change %: +100%
Price: $0.000000^*
Shares after: 400,284
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F2

NVCR transaction

Ordinary Shares

Sale

Transaction value: $646,447
Shares: -50,557
Change %: -13%
Price: $12.79
Shares after: 349,727
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F3, F4

NVCR transaction

Ordinary Shares

Sale

Transaction value: $286,436
Shares: -21,330
Change %: -6.1%
Price: $13.43
Shares after: 328,397
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F3, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NVCR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +258,445
Change %
Price: $0.000000^*
Shares after: 258,445
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 258,445
Exercise price: $13.30
Footnotes: F6

NVCR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +30,072
Change %: +12%
Price: $0.000000^*
Shares after: 288,517
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 30,072
Exercise price: $13.30
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.

Footnote F2

Represents vesting of performance-based restricted stock units.

Footnote F3

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Footnote F4

This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price.

Footnote F5

This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price.

Footnote F6

Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.